Rebalix
Invesco · sheet of 4 September 2026
Invesco · sheet of 4 September 2026ETF sheet · official issuer and register data
Invesco NASDAQ Biotech UCITS ETF Acc
SBIO · IE00BQ70R696 · class Acc · USD · domicile Ireland
Equity · United States · Health careSFDR art. 6
Index tracked: NASDAQ Biotechnology Index Total Return
- TER
- 0.40%+ trans. 0.00%
- Fund size
- 416 m EUR
- Tracking difference
- −0.45%3-year avg
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Synthetic (swap)
- Income
- Accumulating
Launch 6 Nov 2014 · costs from the KID as of 14 Aug 2026 · 179 securities held · 10 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 14 Aug 2026
Redemption and Dealing of Shares:
The Fund's shares are listed on one or more Stock Exchange(s). Investors can buy or sell shares daily through an intermediary directly or on Stock Exchange(s) on which the shares are traded. In exceptional circumstances investors will be permitted to redeem their shares directly from the Umbrella Fund in accordance with the redemption procedures set out in the prospectus, subject to any applicable laws and relevant charges. Investment objective: The investment objective of the Fund is to achieve the total return…
Performance since series start (in euro) — base 100
6 Nov 2014 → 13 Aug 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +51.5% |
| 3 years | +59.7% |
| 5 years | +34.2% |
| 10 years | +121.1% |
| Since series start | +149.7% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 21.67% | 20.96% | 22.23% |
| Max drawdown | −8.42% | −23.94% | −37.98% |
| Sharpe | 1.99 | 0.90 | 0.28 |
| Sortino | 3.22 | 1.32 | 0.40 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · SBIO · IE00BQ70R6961
RebalixSBIO · IE00BQ70R696 · sheet of 4 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +32.91% | +33.43% | −0.52% |
| 2024 | −0.97% | −0.57% | −0.40% |
| 2023 | +4.18% | +4.59% | −0.42% |
| 2022 | −10.47% | −10.12% | −0.35% |
| 2021 | −0.38% | +0.02% | −0.40% |
Holdings
Synthetic replication: top positions of the substitute basket (swap collateral), not the fund’s exposure · 31 Aug 2026 · 179 securities · top-10 weight = 28.1%
| Top holdings | Weight |
|---|---|
| 5.2% | |
| 4.9% | |
| 3.2% | |
| 2.7% | |
| 2.1% | |
| 2.1% | |
| 2.0% | |
| 2.0% | |
| 1.9% | |
| 1.8% |
Listing venues
ESMA register (FIRDS) and official exchange lists
SBIO · Borsa Italiana (ETFplus), Euronext Amsterdam
— · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange
NBTK · Xetra (Deutsche Börse)
+ 20 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00BQ70R696
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BQ70R696
Series, distributions, holdings and documents refresh daily.
Sheet produced on 4 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · SBIO · IE00BQ70R6962